BAY 11-7082

SKU: orb1307179

Description

BAY 11-7082 (also known as BAY 11-7821) is a cell-permeable small molecule that potently inhibits the deubiquitinases USP7 and USP21, and also suppresses NF-κB activation by blocking TNFα-induced IκBα phosphorylation. This dual activity makes it a valuable research tool for studying inflammatory signaling, immune regulation, and cancer pathways in both cellular and animal models.

Research Area

Cell Biology, Neuroscience

Key Properties

• CAS Number: 19542-67-7
• MW: 207.3
• Purity: >98%
• Formula: C₁₀H₉NO₂S
• SMILES: Cc1ccc(cc1)S(=O)(=O)\C=C\C#N
• Target: Kinase
• Solubility: Soluble in DMSO (up to 25 mg/ml) or in Ethanol (up to 15 mg/ml).

Bioactivity

• Target IC50:
  IκBα phosphorylation:10 μM|IκBα phosphorylation:10 μM|USP21:0.96 μM|USP7:0.19 μM
• In Vivo:
  METHODS: To investigate the immunomodulatory effects, BAY 11-7082 (5-10 mg/kg) was injected intraperitoneally into C57BL/6 mice, followed 1 h later by intravenous injection of poly U (50 µg/head) + in vivo-jetPEI. RESULTS: Treatment with BAY 11-7082 inhibits the IFN response in vivo by limiting pDC function when stimulated with TLR ligands. METHODS: To investigate the effects on psoriasiform dermatitis, BAY 11-7082 (20 mg/kg) was injected intraperitoneally into C57BL/6 and NLRP3 KO mice with IMQ-induced psoriasiform lesions once daily for seven days. RESULTS: BAY 11-7082 blunted epidermal thickness, acanthosis and inflammatory infiltrates.BAY 11-7082 decreased the expression of pNF-κB, NLRP3, TNF-α, IL-6 and IL-1β, attenuated the phosphorylation of signal transducers and STAT3, and lowered IL-23 levels.
  Read more...
• In Vitro:
  METHODS: Human colorectal cancer cells HT29 were treated with BAY 11-7082 (10-100 µM) for 1 h, followed by stimulation with TNF (50 ng/mL) for 3-10 min or Flag-TWEAK (200 ng/mL) for 8 h. The expression levels of target proteins were detected by Western Blot. RESULTS: Bay 11-7082 inhibited TWEAK-induced p100 processing and TNF-induced phosphorylation and degradation of IκBα. Both NFκB pathways were significantly blocked at concentrations of 30-100 µM of Bay 11-7082. METHODS: Macrophage RAW264.7 was treated with BAY 11-7082 (15 µM) and LPS (1 µg/mL) for 6 h, and TNF-α levels were measured by ELISA Assay. RESULTS: BAY 11-7082 blocked TNF-α production in LPS-treated RAW264.7 cells, which is an inflammatory response generated by activated NF-κB.
  Read more...
• Cell Research:
  Cells are transfected with siRNA in 96-well microtiter plates and then cultured for 72 hours in complete NSCLC medium, treated with BAY 11-7082 for 12 hours. Cells are incubated with [3H]thymidine for 3 hours. The cells are collected on filters using an automatic cell harvester and radioactivity on the filters is measured by β-scintillation counting.(Only for Reference)
  Read more...

Storage & Handling

• Storage: RT
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

ubiquitin, T-cell, phosphorylation, adhesion, Apoptosis, Autophagy, BAY 117082, BAY 11-7082, BAY 11-7821, BAY 11 7082, B-cell, cytokine, Deubiquitinase, DUBs, I kappa B kinase, leukaemic, IKK, IkB, IkB/IKK, E2-conjugating enzymes, Inhibitor, inhibit, IκBα phosphorylation, IκB, IκB kinase, inflammasome, lymphoma

Compound Identifiers

PubChem CID

5353431

J Guo, X Ma, L Wu, W Zhao, Y Zhang, C Hao, Y Yang, Z Yin, T Xu, Y Zhang, Y Guo, X Cao Inhibition of Nuclear factor kappa B ameliorates bone destruction and osteoclastogenesis in collagen-induced arthritis mice African Health Sciences, (2025)

PubMed: 41640567